Rivaroxaban Versus Aspirin for Prevention of Covert Br
Embolic Stroke of Undetermined Source: NAVIGATE ES

International Journal of Stroke

17, 799-805

DOI: 10.1177/17474930211058012

Citation Report

#	Article	IF	Citations
1	Functional Abilities of an International Post-Stroke Population: Standard Assessment of Global Everyday Activities (SAGEA) Scale. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106329.	2.2	8
2	A Critical Assessment of the Current Pharmacotherapy for the Treatment of Embolic Strokes of Undetermined Source. Expert Opinion on Pharmacotherapy, 2022, 23, 905-915.	3.5	4
3	Posterior Circulation Stroke From Diagnosis to Management, Including Recent Data on Thrombectomy for Basilar Artery Occlusion From the BAOCHE and ATTENTION Trials. International Journal of Stroke, 2022, 17, 712-713.	7.4	6
4	Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials. Canadian Journal of Cardiology, 2023, 39, 187-197.	3.8	1
5	Prevalence and Impact of Cerebral Microbleeds on Clinical and Safety Outcomes in Acute Ischaemic Stroke Patients Receiving Reperfusion Therapy: A Systematic Review and Meta-Analysis. Biomedicines, 2023, 11, 2865.	4.9	17
6	Cerebral Microbleeds and Asundexian in Non-Cardioembolic Ischemic Stroke: Secondary Analyses of the PACIFIC-STROKE Randomized Trial. International Journal of Stroke, 2024, 19, 526-535.	7.4	13
7	Safety and Efficacy of Factor XIa Inhibition With Milvexian for Secondary Stroke Prevention (AXIOMATIC-SSP): A Phase 2, International, Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Trial. Lancet Neurology, The, 2024, 23, 46-59.	43.7	121
8	Apixaban Versus Aspirin for Embolic Stroke of Undetermined Source. NEJM Evidence, 2024, 3, EVIDoa2300235.	10.7	82
9	Combination Antithrombotic Therapy for Reduction of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease. Stroke, 2025, 56, 380-389.	9.1	16
10	Apixaban to Prevent Covert Infarcts After Cryptogenic Stroke in Patients With Atrial Cardiopathy: A Secondary Analysis of the ARCADIA Randomized Clinical Trial. JAMA Neurology, 2025, 82, 220-227.	22.0	17
11	Location, Size, and Risk Factors of Incident Covert Brain Infarcts in Patients With Acute Non-Cardioembolic Ischemic Stroke: PACIFIC-STROKE Trial. European Stroke Journal, 2025, 10, 1413-1420.	5.8	2
12	MRI Findings Intracranial Hemorrhages in ARCADIA-MRI: An Ancillary Study to the ARCADIA Trial. American Journal of Neuroradiology, 2026, 47, 322-328.	3.2	1
13	Antithrombotic Therapy After Successful Catheter Ablation for Atrial Fibrillation. New England Journal of Medicine, 2026, 394, 323-332.	76.6	98
14	Antithrombotic Strategies Targeting the Coagulation Pathway and Incident Covert Brain Infarction: A Systematic Review and Meta-Analysis of Randomized Trials. International Journal of Stroke, 2026, .	7.4	1
15	A Bibliometric Analysis of Cardioembolic Stroke Utilizing HistCite Pro, CiteSpace, and VOSviewer. Medicine (United States), 2026, 105, e49247.	2.1	0
16	Direct Oral Anticoagulants Versus Aspirin for Prevention of Overt and Covert Cerebral Infarction: A Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases, 2026, 35, 108694.	2.2	0